Navigation Links
Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
Date:2/2/2009

FRAZER, Pa., Feb. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the company will exercise its option to license worldwide rights to Lupuzor(TM), an investigational medication for the treatment of Systemic Lupus Erythematosus, based on the promising interim results of the ImmuPharma Phase IIb study. Cephalon will assume all expenses for Phase III studies, regulatory filings and subsequent commercialization of the product.

ImmuPharma PLC received a $15 million upfront fee at the initiation of the deal last year. In exercising its option, Cephalon will pay ImmuPharma a one-time license fee of $30 million. ImmuPharma could receive future cash milestone payments upon the achievement of certain regulatory and sales milestones, as well as royalties on commercial sales of Lupuzor. The various cash milestone payments (including the option and license fees) may total up to approximately $500 million.

"We are pleased that this Phase IIb study shows a favorable efficacy and safety profile for Lupuzor," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon. "We will initiate plans to implement pivotal Phase III clinical trials this year."

"These study results are encouraging and bring us one step closer to providing the first specific medication for the treatment of lupus to patients living with this chronic, potentially life-threatening disease," said Frank Baldino, Jr., Ph.D., chairman and CEO of Cephalon. "Lupuzor recently received a notice of allowance for its novel composition of matter patent, which will support our development of the product. If our efforts are successful, this product and our recent deal with Ception Therapeutics will allow us to build a business unit focused on i
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... in German . , Whether it,s CD packaging, c...o Frequency Identification) are increasingly findi...ible to label objects or goods and identify them a...canner can read and process the data contained in ...der production conditions of up to 100 degrees Cel...
(Date:11/24/2009)...HEIM, Ontario, Nov. 24 D...ring the assets of Hyland Seeds, a division of Tho...of Hyland Seeds will further expand Dow AgroScienc...tes the introduction of SmartStax(TM) in 2010 ...chnology in corn in 2012. The transactional close ...
(Date:11/24/2009)... Nov. 24 /PRNewswire-Asia/ -- NOD Pharmaceuticals ...e (PTO) has allowed the patent application for,its..., NOD technology is a highly efficient appr...adhesive nano-particles to enable oral delivery of...echnology is a platform technology,that can be app...
(Date:11/24/2009)...ficacy endpoint has been met for patients with adv...,, QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ ... (the "Company"), a global biopharmaceutical compa...y announced positive efficacy data from a Phase 2 ...e, AEZS-108 (formerly AN-152), in patients with ad...
Breaking Biology Technology:Intelligence inside metal components 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...is. Modine Manufacturing Company announced Satu...p Liberty at the 19th Annual Agricultural Machiner...vehicle features an air conditioning system that d...ons, cools faster than current systems and is more...nt of space under the hood. , ,Carbon dioxide is a...
...e, Wis. MobilePro Corp. announced today the com...on.net , a Janesville-based Internet services prov... subscribers, $2 million in annualized revenue and...action, which is subject to the signing of definit...s expected to close in June 2004. The terms of the...
...J. Weymier, PMP, is founder of PM Maturity and joi.... He will be exploring the various aspects of proj...his article is part two of the series. , , TQM - ...e said, Survival is optional. Is it? In a way, it ... worked during the past few years. Id modify the q...
Other Biology Technology:Part 2 Project performance Get on the path to continuous improvement 2Part 2 Project performance Get on the path to continuous improvement 3
(Date:11/24/2009)...ies from collapsing have been true life-savers. Bu...ded -- once the arteries are strengthened, they be...e but to leave them in place. , Prof. Meital Zil...edical Engineering has developed a new patent-pend...e needed, then dissolves. , "Our new composite f...
(Date:11/24/2009)...9) -- The Wildlife Conservation Society (WCS) anno...ning population of Siberian tigers has likely decl...ing and habitat loss. , WCS says the... needs to be done to protect remaining populations...report was released by the Siberian Tiger Monitori...
(Date:11/24/2009)...search on bacterial communities throughout six lar...poral patterns, suggesting that scientists could u...mate change in the polar regions. The study, publi... Academy of Sciences Early Edition, shows that ba...hronously over time, correlating with seasonal shi...
Breaking Biology News(10 mins):A coating for life 2Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 1Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 2Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 3Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 4Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 5Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 6Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 1Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 2Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 3Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 4HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 1HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 2HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 3
...ve made a breakthrough in understanding a virus wh...ts to wild carnivores including lions, African wil... of how canine distemper Virus (CDV) jumps across ...lead to a more effective monitoring and control of...species are quite common, very little is known abo...
...pathologists have identified a new molecular targe...o reduce fat transport to adipocytes (fat cells) i...rs, like diabetes. , Detailed in the Oct. 18 onl...he Journal of Clinical Investigation, the findings...ocyte LDL receptor-related protein 1 (LRP1), provi...
...The human genome would have been an impossible jig...oday at 3.30 pm he will receive the Gruber Genetic... Conference in San Diego. , Olson created a way...ed it to the yeast genome, and made the human geno... apply genome science to real biological problemss...
Other Biology News:Research sheds new light on how diseases jump across species 2'Knocking out' cell receptor may help block fat deposits in tissues, prevent weight gain 2Maynard Olson receives $500,000 Gruber Genetics Prize 2
Giemsa stain from Sigma-Aldrich
Bovine Serum, Sterile Filtered from Meridian Life Science, Inc.
CORNING IVF CULTURE DISH, 60 X 15MM, PS, STERILE from Sigma-Aldrich
LV-2080 Solvent Switching Valve from JASCO
Biology Products: